Compass Pathways has no approved product to sell. It has, by its own account, kept medical science liaisons in the field for about two and a half years, and it is now hiring a commercial sales force on top of them, all before it has a drug cleared to market. Medical science liaisons are the field-based scientific staff who engage physicians and researchers on clinical data and disease understanding, non-promotional by design and distinct from a sales team. Standing up the scientific field function years early, and now the commercial one, ahead of any approval is a concrete signal about how close a company believes it is.
What Compass has built, and what it is hiring now
Compass’s medical science liaison team is not new. The company said on its August 2026 earnings call that its liaisons have been engaging treatment sites for about two and a half years, which places the effort back around early 2024, well before any filing. What is open on Compass’s own careers board now is different. Its medical science liaison postings from earlier in the year have largely closed. The field hiring that is live today is commercial: dozens of neuroscience sales-specialist roles across US cities. The scientific field team has been in place for over two years, in other words, and the company has moved on to staffing the sales force that only matters if a product reaches the market. A company assembling both layers, science first and now commercial, is not filling a single post; it is building a launch organization.
Why building the scientific team early is the tell
Sales representatives can be hired quickly once a product is approved and pricing is set; that function does not need to exist years in advance. Medical science liaisons are different. They require deep product and disease-state training, and companies build the function ahead of launch precisely because establishing scientific credibility with prescribers, key opinion leaders, and academic centers takes time that cannot be compressed into the weeks between approval and launch. A company that put that team in place around early 2024 and is now layering a sales force on top, ahead of its own targeted filing, is putting money behind an approval timeline it believes in.
How this fits against the rest of Compass’s year
This desk has tracked Compass’s clinical and regulatory position closely. Both pivotal Phase 3 trials of COMP360 in treatment-resistant depression have read out positive. The company is running a rolling NDA on track to complete all modules in the fourth quarter of 2026. The FDA awarded COMP360 a Commissioner’s National Priority Voucher in April, a designation that can shorten the post-filing review. And a second COMP360 program, the Redefine Study in PTSD, has begun recruitment as a Phase 2b/3 trial. The field buildout, scientific and now commercial, is the infrastructure complement to that regulatory picture: evidence the company is preparing to launch alongside its FDA review, ahead of any approval decision.
What a field team can’t prove about approval odds
A field team, however far along, is not evidence about COMP360’s approval odds; companies have built commercial infrastructure ahead of rejections before, and Compass’s own materials note that its continued work is contingent on regulatory approval. Hiring is a soft signal rather than a disclosure: postings open and close, as Compass’s own medical science liaison listings just did, and a field organization assembled now can be paused if a submission stumbles. The buildout shows what the company is planning for. It says nothing about what the FDA will decide.
A company’s own hiring choices are a form of disclosure, whether or not they are framed that way.
Compass keeping a scientific field team in place for more than two years, and now staffing the commercial one, ahead of its targeted NDA completion is a specific data point about how the company itself is pricing its own approval odds, distinct from anything a trial readout or an analyst note can offer. It is not proof of anything about COMP360’s clinical merits. It is evidence that Compass is spending money now, on functions with no purpose until an approval exists, because it believes that approval is close enough to be worth building toward today.